Dr. Kyle Greenway is a psychiatrist and clinician-scientist at the Jewish General Hospital/Lady Davis Institute and assistant professor at McGill University, recently awarded an FRQS chercheur-boursier salary award. He completed his residency in psychiatry at McGill and a postdoctoral fellowship at Imperial University’s psychedelic research centre, as well as McGill’s clinical Investigator Program. He founded and directs the JGH’s ketamine-therapy for TRD program, and co-leads the ‘Psychedelics and Contemplation’ research group with Dr. Michael Lifshitz, affiliated with McGill’s world-famous Division of Social and Transcultural Psychiatry, which studies the therapeutic potential, neural underpinnings, and social contexts of altered states of consciousness.